Argus® II Retinal Prosthesis System Post-Market Surveillance Study

Exclusion Criteria

• •Ocular diseases or conditions that could prevent Argus II from working (e.g. optic nerve disease, central retinal artery or vein occlusion, history of retinal detachment, trauma, severe strabismus, etc.)
• •Ocular structures or conditions that could prevent the successful implantation of the Argus II Implant or adequate healing from surgery (e.g. extremely thin conjunctiva; axial length \<20.5 mm or \> 26 mm; corneal ulcers; choroidal neovascularization in the area of the intended tack location, etc.)
• •Ocular diseases or conditions (other than cataracts) that prevent adequate visualization of the inner structures of the eye (e.g. corneal opacity)
• •Pre-disposition to eye rubbing
• •Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:
• •* cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease,
• •* psychiatric disease including diagnosed forms of depression;
• •* does not speak a principal language associated with the region, and
• •* deafness or selective frequency hearing loss that prevents hearing device alarms and alerts
• •Participants who are pregnant or wish to become pregnant during the course of the study
• •Participation in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study;
• •Conditions likely to limit life to less than 1 year from the time of inclusion.